$43.0M in CY2024 Part D spend29K claims · 15K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Tapinarof used for?
Tapinarof is a Aryl Hydrocarbon Receptor Agonist medication tracked in Medicare Part D.
Is there a generic for Tapinarof?
No. Tapinarof is brand-only with no generic equivalents currently in market.
How much does my plan pay for Tapinarof?
Across 329 Part D plans, Tapinarof averages $25.29/unit (NADAC). Lowest available: $25.29/unit. Highest in distribution: $25.29/unit.
Is Tapinarof on the FDA shortage list?
No. Tapinarof is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.